Actively Recruiting
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-08-08
20
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.
CONDITIONS
Official Title
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign informed consent.
- Age 18 years or older.
- Confirmed unresectable or metastatic refractory cancer with measurable disease per RECIST version 1.1.
- Progressive disease after multiple lines of treatment.
- Eastern Cooperative Oncology Group Performance Status of 3 or less.
- Completed prior therapy at least 2 weeks before the 68Ga-RGD PET/CT scan with resolved significant toxicity below Grade 2 or baseline.
- Adequate blood counts: ANC 2 1000 cells/mm3, platelet count 2 50,000/mm3, hemoglobin 2 8 g/dL.
- Blood chemistry within limits: AST, ALT, alkaline phosphatase 2 5 times ULN, total bilirubin 2 3 times ULN, creatinine 2 3 times ULN.
- Able to remain still for 30 to 60 minutes during scans.
You will not qualify if you...
- Use of any chemical anticoagulants including antiplatelet agents (except aspirin).
- Class 3 or 4 congestive heart failure.
- Significant bleeding within 2 weeks before trial entry.
- Pregnant or lactating women.
- Major surgery within 28 days before study or planned surgery within 6 weeks.
- Another active cancer requiring treatment within the past 2 years.
- Active uncontrolled infection needing systemic therapy.
- Psychiatric or social conditions interfering with study compliance.
- Unable to undergo PET/CT scan due to weight over 350 lbs.
- INR greater than 1.2 or PTT more than 5 seconds above normal limit.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
H
Haojun Chen, MD, PhD
CONTACT
H
Hao Fu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here